Cargando…

Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management

Hereditary bleeding disorders include a group of diseases with abnormalities of coagulation. Prior to 1990, infection with hepatitis C virus (HCV) was mainly transmitted via pooled plasma products as a treatment for hereditary bleeding disorders. Anti-HCV positivity in these patients may be as high...

Descripción completa

Detalles Bibliográficos
Autores principales: Papadopoulos, Nikolaos, Argiana, Vasiliki, Deutsch, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hellenic Society of Gastroenterology 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759611/
https://www.ncbi.nlm.nih.gov/pubmed/29333065
http://dx.doi.org/10.20524/aog.2017.0204
_version_ 1783291239393656832
author Papadopoulos, Nikolaos
Argiana, Vasiliki
Deutsch, Melanie
author_facet Papadopoulos, Nikolaos
Argiana, Vasiliki
Deutsch, Melanie
author_sort Papadopoulos, Nikolaos
collection PubMed
description Hereditary bleeding disorders include a group of diseases with abnormalities of coagulation. Prior to 1990, infection with hepatitis C virus (HCV) was mainly transmitted via pooled plasma products as a treatment for hereditary bleeding disorders. Anti-HCV positivity in these patients may be as high as >70% in some areas, while some of them have also been coinfected with human immunodeficiency virus. Since about 20% of HCV-infected patients clear the infection naturally, chronic HCV infection represents a significant health problem in this group of patients. Mortality due to chronic HCV infection is estimated to be >10 times higher in patients with hemophilia than in the general population, and is mainly due to liver cirrhosis and hepatocellular carcinoma. The antiviral treatment of HCV in patients with hereditary bleeding disorders is not different from that of any other infected patients. Nevertheless, many patients with hereditary bleeding disorders have declined (Peg)interferon-based treatment because of side effects. In recent years, multiple orally administrated direct-acting antivirals (DAAs) have been approved for HCV treatment. Unfortunately, there is not much experience from treating these patients with DAA regimens, as major studies and real-life data did not include adequate numbers of patients with inherited hemorrhagic disorders. However, the available data indicate that DAAs have an excellent safety profile with a sustained virological response rate of >90%.
format Online
Article
Text
id pubmed-5759611
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hellenic Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-57596112018-01-12 Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management Papadopoulos, Nikolaos Argiana, Vasiliki Deutsch, Melanie Ann Gastroenterol Invited Review Hereditary bleeding disorders include a group of diseases with abnormalities of coagulation. Prior to 1990, infection with hepatitis C virus (HCV) was mainly transmitted via pooled plasma products as a treatment for hereditary bleeding disorders. Anti-HCV positivity in these patients may be as high as >70% in some areas, while some of them have also been coinfected with human immunodeficiency virus. Since about 20% of HCV-infected patients clear the infection naturally, chronic HCV infection represents a significant health problem in this group of patients. Mortality due to chronic HCV infection is estimated to be >10 times higher in patients with hemophilia than in the general population, and is mainly due to liver cirrhosis and hepatocellular carcinoma. The antiviral treatment of HCV in patients with hereditary bleeding disorders is not different from that of any other infected patients. Nevertheless, many patients with hereditary bleeding disorders have declined (Peg)interferon-based treatment because of side effects. In recent years, multiple orally administrated direct-acting antivirals (DAAs) have been approved for HCV treatment. Unfortunately, there is not much experience from treating these patients with DAA regimens, as major studies and real-life data did not include adequate numbers of patients with inherited hemorrhagic disorders. However, the available data indicate that DAAs have an excellent safety profile with a sustained virological response rate of >90%. Hellenic Society of Gastroenterology 2018 2017-10-26 /pmc/articles/PMC5759611/ /pubmed/29333065 http://dx.doi.org/10.20524/aog.2017.0204 Text en Copyright: © Hellenic Society of Gastroenterology http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Invited Review
Papadopoulos, Nikolaos
Argiana, Vasiliki
Deutsch, Melanie
Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
title Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
title_full Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
title_fullStr Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
title_full_unstemmed Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
title_short Hepatitis C infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
title_sort hepatitis c infection in patients with hereditary bleeding disorders: epidemiology, natural history, and management
topic Invited Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5759611/
https://www.ncbi.nlm.nih.gov/pubmed/29333065
http://dx.doi.org/10.20524/aog.2017.0204
work_keys_str_mv AT papadopoulosnikolaos hepatitiscinfectioninpatientswithhereditarybleedingdisordersepidemiologynaturalhistoryandmanagement
AT argianavasiliki hepatitiscinfectioninpatientswithhereditarybleedingdisordersepidemiologynaturalhistoryandmanagement
AT deutschmelanie hepatitiscinfectioninpatientswithhereditarybleedingdisordersepidemiologynaturalhistoryandmanagement